Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
about
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta 2 -agonists (LABA) for adults with asthmaClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseLong-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerationsA systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort studyTiotropium in asthma: a systematic reviewRisk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialTiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trialSafety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm?Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.Long-acting muscarinic antagonists.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized StudiesDoes Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease?Tiotropium formulations and safety: a network meta-analysisResponse to Wise et al. (Tiotropium safety in real life populations).Authors' response to Walker et al.Inhaled bronchodilators and acute myocardial infarction: a nested case-control study.Factors associated with the incidence of serious adverse events in patients admitted with COPD acute exacerbation.Update in chronic obstructive pulmonary disease 2013.Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives.
P2860
Q24186370-5EC1FC82-7FED-454E-A3B4-3737ED306DF3Q24187031-73D0479C-201C-4760-8C28-F973AECC86FCQ24187322-11617BEC-7225-4B82-836E-C0553CA8CC7CQ27023223-D5573AAA-CE1A-4D71-9D9C-62A0FACA26B7Q28067579-A0CA47B6-BE6F-4575-9B66-9CAA9E408A41Q30820402-92B9B109-5CA4-4665-ADBE-5CB930E48041Q30877371-0707C1E3-E8C0-4674-8BC8-4B85E82BFCA2Q33590384-ED6D4BFE-7EF1-482E-974C-BCFEC67DCB28Q35112216-375F004F-8E73-40DA-A2CE-379564BFE801Q35675649-9D2844BC-98DD-4DFB-AD9E-A2C4F5A0CEB6Q35762406-7C624077-1116-48C8-95E6-1E35EC534859Q35766346-960065F9-40D0-4957-8DD5-AA52C752EB11Q36456873-CCB95D53-7DF9-4C42-8429-EB38F0047E4AQ36802125-ACB0A989-9F1C-44A5-8368-F87BC976A1F3Q36907742-1ADDA5CE-4034-4843-83C5-A26E8ECCD8DAQ37446886-A30BC3F0-D582-4112-A94E-F27D4DF9F9C0Q38189313-09EDC070-A2D1-4D40-B975-C5D46A43B583Q38199533-5FCE8258-FE8F-45DC-8A57-FFBCE9A84EB0Q38258538-A0BC116C-FDB1-40A0-A1EC-C971C236F8D1Q38537326-6DC33C6C-7110-410A-8E37-934C96FF0081Q38592062-2F0F8A66-C6EC-47C0-AC8A-D0C8E64E9A69Q38604650-8BCC1CE9-C93A-4DEA-B4A6-F44F72DBD13DQ38749254-B7ADF74A-C50D-4465-B0A3-1FC349FA051CQ39137733-202614F6-1CF1-4B67-A8D4-4FECE3C6950FQ42382854-263C9FFC-4F71-4E81-AB83-E1EA1ABB6EACQ46038122-C1352FDD-E291-4C19-8E7D-B2F1DBE5D657Q47107761-00656B0A-0233-4FB7-A3C5-A3FEEB756AB4Q47825043-1CC186DB-7323-459B-94E8-B162EA193FADQ51082449-35A4C613-830E-467D-A926-780E7A58A454Q55131618-61CA5D02-719A-40E9-8C58-9F7C9A7E2C45
P2860
Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@en
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@nl
type
label
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@en
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@nl
prefLabel
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@en
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@nl
P2093
P1476
Use of tiotropium Respimat Sof ...... rtality in patients with COPD.
@en
P2093
Ana Afonso
Bruno C Stricker
Guy G O Brusselle
Katia M C Verhamme
Miriam C J M Sturkenboom
Silvana Romio
P304
P356
10.1183/09031936.00005813
P577
2013-03-21T00:00:00Z